Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy
Researchers investigated the risk of T-cell malignant neoplasms and any second primary malignant neoplasms in patients receiving CAR T-cell therapy for hematologic malignancies.